- Investing Ideas
- /
- Biotech Breakthroughs
Biotech Breakthroughs
UPDATED Apr 12, 2024
Companys with strong funding and high growth potential
86 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
SRPT | US$122.87 | -2.5% | 0.2% | US$11.7b | US$164.59 | PS9.3x | E42.3% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$12.57 | -8.6% | 123.4% | US$3.7b | US$26.43 | PS2903.5x | E61.7% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$5.56 | 1.1% | 4.7% | US$368.0m | US$21.60 | PS25.5x | E52.8% | n/a | Pharmaceuticals & Biotech | ||
ABEO | US$7.55 | 1.5% | 170.6% | US$213.1m | US$21.00 | PS59x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
CAPR | US$6.25 | -7.0% | 42.7% | US$196.3m | US$21.00 | PS7.8x | E59.4% | n/a | Pharmaceuticals & Biotech | ||
PRRU.F | AU$0.24 | 0% | n/a | AU$445.8m | n/a | PS113.4x | E60.3% | n/a | Pharmaceuticals & Biotech | ||
IMM | AU$0.38 | -7.4% | 53.1% | AU$445.8m | AU$1.30 | PS113.4x | E60.3% | n/a | Pharmaceuticals & Biotech | ||
MEOB.F | AU$0.60 | 0% | n/a | AU$980.5m | n/a | PS85x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
0A4W | US$17.12 | -5.5% | -4.0% | US$2.9b | US$29.34 | PS3.9x | E40.9% | n/a | Pharmaceuticals & Biotech | ||
LLA | UK£0.30 | 0% | n/a | UK£9.7m | UK£2.10 | PS261.3x | E88.7% | n/a | Pharmaceuticals & Biotech | ||
PGEN | US$1.42 | 1.4% | 35.2% | US$360.9m | US$9.00 | PS56.8x | E55.5% | n/a | Pharmaceuticals & Biotech | ||
0IV3 | US$3.85 | 15.2% | 95.0% | US$2.2b | US$5.38 | PS9044.3x | E62.1% | n/a | Pharmaceuticals & Biotech | ||
GNFT | €3.58 | 1.5% | -10.5% | €165.0m | €10.12 | PS4.8x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
0W4N | €47.11 | 2.4% | -29.3% | €820.3m | €97.61 | PS12x | E44.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €378.02 | -2.3% | -1.3% | €20.9b | €471.19 | PS17.6x | E56.3% | n/a | Pharmaceuticals & Biotech | ||
SBFM | US$0.08 | -21.5% | -88.2% | US$8.7m | US$3.00 | PB0.4x | E134.4% | n/a | Pharmaceuticals & Biotech | ||
KRTX | US$329.83 | 3.3% | 80.7% | US$12.6b | US$326.92 | PS19238.9x | E60.1% | n/a | Pharmaceuticals & Biotech | ||
GNFT.F | €2.98 | 0% | n/a | €166.5m | €8.34 | PS4.4x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
ARX | AU$0.56 | -0.9% | -46.2% | AU$194.5m | AU$1.02 | PS3.2x | E115.3% | n/a | Pharmaceuticals & Biotech | ||
ARX | AU$0.56 | -1.8% | -46.9% | AU$194.5m | AU$1.01 | PS3.2x | E115.3% | n/a | Pharmaceuticals & Biotech | ||
ARGN.F | €383.74 | 0% | n/a | €20.9b | €477.64 | PS17.6x | E56.3% | n/a | Pharmaceuticals & Biotech | ||
MESO | AU$5.37 | -7.4% | -21.9% | AU$980.5m | AU$6.87 | PS84.8x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
CASI | US$2.60 | -18.8% | -27.6% | US$34.4m | US$12.00 | PB1.4x | E57.6% | n/a | Pharmaceuticals & Biotech | ||
VCEL | US$47.90 | -6.2% | 60.6% | US$2.4b | US$53.07 | PS11.7x | E49.4% | n/a | Pharmaceuticals & Biotech |